• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

喹诺酮类药物抑制 IIA 拓扑异构酶和靶介导耐药性的结构基础。

Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance.

机构信息

Platform Technology and Science, GlaxoSmithKline, Medicines Research Centre, Stevenage, Hertfordshire, UK.

出版信息

Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. doi: 10.1038/nsmb.1892. Epub 2010 Aug 29.

DOI:10.1038/nsmb.1892
PMID:20802486
Abstract

Quinolone antibacterials have been used to treat bacterial infections for over 40 years. A crystal structure of moxifloxacin in complex with Acinetobacter baumannii topoisomerase IV now shows the wedge-shaped quinolone stacking between base pairs at the DNA cleavage site and binding conserved residues in the DNA cleavage domain through chelation of a noncatalytic magnesium ion. This provides a molecular basis for the quinolone inhibition mechanism, resistance mutations and invariant quinolone antibacterial structural features.

摘要

喹诺酮类抗菌药物已经被用于治疗细菌感染超过 40 年。莫西沙星与鲍曼不动杆菌拓扑异构酶 IV 的晶体结构显示,楔形喹诺酮类化合物堆积在 DNA 切割位点的碱基对之间,通过螯合非催化性镁离子与 DNA 切割结构域中的保守残基结合。这为喹诺酮类抑制机制、耐药突变和不变的喹诺酮类抗菌结构特征提供了分子基础。

相似文献

1
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance.喹诺酮类药物抑制 IIA 拓扑异构酶和靶介导耐药性的结构基础。
Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. doi: 10.1038/nsmb.1892. Epub 2010 Aug 29.
2
Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.通过引入与金属离子无关的药物-酶相互作用来克服拓扑异构酶 IV 介导的喹诺酮类耐药性。
ACS Chem Biol. 2013 Dec 20;8(12):2660-8. doi: 10.1021/cb400592n. Epub 2013 Sep 30.
3
Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.与炭疽杆菌拓扑异构酶 IV 的药物相互作用:喹诺酮类药物作用和耐药的生化基础。
Biochemistry. 2012 Jan 10;51(1):370-81. doi: 10.1021/bi2013905. Epub 2011 Dec 16.
4
Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance.拓扑异构酶 IV-喹诺酮相互作用是通过水-金属离子桥介导的:喹诺酮类耐药的机制基础。
Nucleic Acids Res. 2013 Apr;41(8):4628-39. doi: 10.1093/nar/gkt124. Epub 2013 Mar 4.
5
Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge.炭疽芽孢杆菌GrlAV96A拓扑异构酶IV,一种不影响水-金属离子桥的喹诺酮耐药性突变。
Antimicrob Agents Chemother. 2014 Dec;58(12):7182-7. doi: 10.1128/AAC.03734-14. Epub 2014 Sep 22.
6
Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases.对IIA型拓扑异构酶喹诺酮-DNA切割复合物的结构洞察。
Nat Struct Mol Biol. 2009 Jun;16(6):667-9. doi: 10.1038/nsmb.1604. Epub 2009 May 17.
7
Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU.喹诺酮耐药决定区 GyrA 和 ParC 中的氨基酸取代与鲍曼不动杆菌和不动杆菌基因组种 13TU 的喹诺酮耐药相关。
J Microbiol Immunol Infect. 2012 Apr;45(2):108-12. doi: 10.1016/j.jmii.2011.09.001. Epub 2011 Dec 6.
8
Molecular determinants of the bacterial resistance to fluoroquinolones: a computational study.细菌对氟喹诺酮类药物耐药性的分子决定因素:一项计算研究。
Curr Comput Aided Drug Des. 2013 Jun;9(2):281-8. doi: 10.2174/15734099113099990004.
9
Development of a pyrosequencing assay for rapid assessment of quinolone resistance in Acinetobacter baumannii isolates.开发一种焦磷酸测序检测法,快速评估鲍曼不动杆菌分离株中的喹诺酮类药物耐药性。
J Microbiol Methods. 2011 Jul;86(1):115-8. doi: 10.1016/j.mimet.2011.04.007. Epub 2011 Apr 13.
10
Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from Klebsiella pneumoniae and comparison with a related Streptococcus pneumoniae complex.肺炎克雷伯菌拓扑异构酶IV喹诺酮稳定切割复合物的结构及其与相关肺炎链球菌复合物的比较。
Acta Crystallogr D Struct Biol. 2016 Apr;72(Pt 4):488-96. doi: 10.1107/S2059798316001212. Epub 2016 Mar 24.

引用本文的文献

1
Quinolone Resistance and Zoonotic Potential of from Domestic Animals in Brazil.巴西家畜中喹诺酮耐药性及人畜共患病潜力
Antibiotics (Basel). 2025 Aug 20;14(8):843. doi: 10.3390/antibiotics14080843.
2
Resistance Response and Regulatory Mechanisms of Ciprofloxacin-Induced Resistant Typhimurium Based on Comprehensive Transcriptomic and Metabolomic Analysis.基于综合转录组学和代谢组学分析的环丙沙星诱导的耐药鼠伤寒沙门氏菌的抗性反应及调控机制
Antibiotics (Basel). 2025 Jul 29;14(8):767. doi: 10.3390/antibiotics14080767.
3
Antibiotic-Induced Bacterial Cell Death: A "Radical" Way of Dying?

本文引用的文献

1
Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis.检测肠道病毒 71 型 IgM 抗体用于早期诊断的性能。
PLoS One. 2010 Jun 30;5(6):e11388. doi: 10.1371/journal.pone.0011388.
2
Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases.对IIA型拓扑异构酶喹诺酮-DNA切割复合物的结构洞察。
Nat Struct Mol Biol. 2009 Jun;16(6):667-9. doi: 10.1038/nsmb.1604. Epub 2009 May 17.
3
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.有害病菌,无药可医:谨防“ESKAPE”!美国传染病学会的最新报告
抗生素诱导的细菌细胞死亡:一种“激进”的死亡方式?
Curr Top Microbiol Immunol. 2025 Aug 9. doi: 10.1007/82_2024_284.
4
Bacterial type II topoisomerases cleave DNA in a species-specific manner.细菌II型拓扑异构酶以物种特异性方式切割DNA。
bioRxiv. 2025 Jul 28:2025.07.28.667256. doi: 10.1101/2025.07.28.667256.
5
Structural basis of topoisomerase targeting by delafloxacin.达氟沙星作用于拓扑异构酶的结构基础
Nat Commun. 2025 Jul 1;16(1):5829. doi: 10.1038/s41467-025-60688-3.
6
Antibiotic-persistent bacterial cells exhibiting low-level ROS are eradicated by ROS-independent membrane disruption.表现出低水平活性氧(ROS)的抗生素持续性细菌细胞可通过不依赖ROS的膜破坏作用被根除。
mBio. 2025 Aug 13;16(8):e0119925. doi: 10.1128/mbio.01199-25. Epub 2025 Jun 30.
7
Towards catalytic fluoroquinolones: from metal-catalyzed to metal-free DNA cleavage.迈向催化氟喹诺酮类药物:从金属催化到无金属DNA切割
RSC Med Chem. 2025 Mar 5. doi: 10.1039/d4md00984c.
8
DNA repair is essential for growth on thiosulfate-citrate-bile salts-sucrose (TCBS) medium.DNA修复对于在硫代硫酸盐-柠檬酸盐-胆盐-蔗糖(TCBS)培养基上生长至关重要。
J Bacteriol. 2025 Apr 17;207(4):e0000425. doi: 10.1128/jb.00004-25. Epub 2025 Mar 26.
9
DNA repair is essential for growth on Thiosulfate-Citrate-Bile Salts-Sucrose (TCBS) Medium.DNA修复对于在硫代硫酸盐-柠檬酸盐-胆盐-蔗糖(TCBS)培养基上生长至关重要。
bioRxiv. 2025 Jan 11:2025.01.10.632459. doi: 10.1101/2025.01.10.632459.
10
How Do Gepotidacin and Zoliflodacin Stabilize DNA-Cleavage Complexes with Bacterial Type IIA Topoisomerases? 2. A Single Moving Metal Mechanism.吉波达辛和佐利弗达辛如何与细菌IIA型拓扑异构酶稳定DNA切割复合物?2. 单一移动金属机制。
Int J Mol Sci. 2024 Dec 24;26(1):33. doi: 10.3390/ijms26010033.
Clin Infect Dis. 2009 Jan 1;48(1):1-12. doi: 10.1086/595011.
4
Structural basis for gate-DNA recognition and bending by type IIA topoisomerases.IIA型拓扑异构酶对门控DNA识别与弯曲的结构基础
Nature. 2007 Dec 20;450(7173):1201-5. doi: 10.1038/nature06396.
5
Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.革兰氏阴性和革兰氏阳性II型DNA拓扑异构酶介导的氟喹诺酮类药物DNA切割的热点共识
Nucleic Acids Res. 2007;35(18):6075-85. doi: 10.1093/nar/gkm653. Epub 2007 Aug 30.
6
Drugs for bad bugs: confronting the challenges of antibacterial discovery.对抗耐药菌的药物:应对抗菌药物研发的挑战
Nat Rev Drug Discov. 2007 Jan;6(1):29-40. doi: 10.1038/nrd2201. Epub 2006 Dec 8.
7
X-Ray crystallographic, NMR and antimicrobial activity studies of magnesium complexes of fluoroquinolones - racemic ofloxacin and its S-form, levofloxacin.氟喹诺酮类镁配合物——外消旋氧氟沙星及其S型异构体左氧氟沙星的X射线晶体学、核磁共振和抗菌活性研究
J Inorg Biochem. 2006 Nov;100(11):1755-63. doi: 10.1016/j.jinorgbio.2006.06.011. Epub 2006 Jul 4.
8
Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents.细菌拓扑异构酶抑制剂:喹诺酮类和吡啶酮类抗菌剂。
Chem Rev. 2005 Feb;105(2):559-92. doi: 10.1021/cr030101q.
9
Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions.在镁离子存在的情况下,环丙沙星会影响DNA旋转酶A的构象平衡。
J Mol Biol. 2001 Aug 3;311(1):195-203. doi: 10.1006/jmbi.2001.4838.
10
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.大肠杆菌DNA促旋酶gyrB基因中的喹诺酮耐药决定区。
Antimicrob Agents Chemother. 1991 Aug;35(8):1647-50. doi: 10.1128/AAC.35.8.1647.